Gilead, Parion Sciences to co-develop pulmonary drugs

Aug 15 (Reuters) - Gilead Sciences Inc. (GILD.O: Quote, Profile, Research) said it entered into an agreement with privately held pharmaceutical company Parion Sciences Inc. to co-develop drug candidates for pulmonary disease.

The agreement grants Gilead worldwide commercialization rights to P-680, an epithelial sodium channel inhibitor, for the treatment of pulmonary diseases.

Under the terms, Gilead will provide an upfront payment of $5 million for the license and make an additional $5 million investment in Parion.

(Reporting by Jennifer Robin Raj in Bangalore)

((Editing by Vinu Pilakkott; Reuters Messaging:aruna.jennifer.reuters.com@reuters.net; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800)) Keywords: GILEAD CODEVELOPMENT/

(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS2153